Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission – – Strengthened ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback